GGrantIndex
← Leaderboards

Nuala Jennings Meyer

University Of Chicago

$12,062,038
Attributed
$12,887,678
Total exposure
11
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY200725
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,887,678 · 11

By mechanism

R01$4,865,406 · 3
R35$3,880,499 · 1
T32$1,466,639 · 1
U01$1,144,421 · 1
K23$685,260 · 1
R56$614,248 · 1

Top collaborators

Most similar at University Of Chicago

Same institution · by research overlap

Others in their field

Top investigators on “Sepsis

Research focus

SepsisCohortPlasmaGeneticCritical IllnessPathway InteractionsMortalityResearch PersonnelMolecularPreventionLungCessation Of LifeMediatingPhenotypeSyndromeImmune ResponseAmericanFutureRisk FactorsPlasma ProteinsPermeabilityPharmacotherapyProteinsCohort Studies

Grant awards (29)

Investigating Individual Susceptibility and Host Response in Acute Respiratory Distress Syndrome$975,000
R35 · FY2025 · HL · contact PI
Phenotyping ARDS, Pneumonia, and Sepsis over time to elucidate shared and distinct trajectories ofillness and recovery$634,751
U01 · FY2025 · HL · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$334,226
T32 · FY2025 · HL · contact PI
Investigating Individual Susceptibility and Host Response in Acute Respiratory Distress Syndrome$955,499
R35 · FY2024 · HL · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$577,722
T32 · FY2024 · HL · contact PI
Phenotyping ARDS, Pneumonia, and Sepsis over time to elucidate shared and distinct trajectories ofillness and recovery$350,420
U01 · FY2024 · HL · contact PI
Investigating Individual Susceptibility and Host Response in Acute Respiratory Distress Syndrome$975,000
R35 · FY2023 · HL · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$554,691
T32 · FY2023 · HL · contact PI
Phenotyping ARDS, Pneumonia, and Sepsis over time to elucidate shared and distinct trajectories ofillness and recovery$159,250
U01 · FY2023 · HL · contact PI
Investigating Individual Susceptibility and Host Response in Acute Respiratory Distress Syndrome$975,000
R35 · FY2022 · HL · contact PI
Targeting Angiopoietin-2 in ARDS$447,835
R01 · FY2021 · HL · contact PI
Mentoring Patient-Oriented Research to Promote ARDS Precision Medicine$124,478
K24 · FY2021 · HL · contact PI
Targeting Angiopoietin-2 in ARDS$479,393
R01 · FY2020 · HL · contact PI
Reconsidering the IL-1 axis in sepsis-associated ARDS$473,676
R01 · FY2020 · HL · contact PI
Reconsidering the IL-1 axis in sepsis-associated ARDS$511,344
R01 · FY2019 · HL · contact PI
Targeting Angiopoietin-2 in ARDS$511,156
R01 · FY2019 · HL · contact PI
Targeting Angiopoietin-2 in ARDS$545,608
R01 · FY2018 · HL · contact PI
Reconsidering the IL-1 axis in sepsis-associated ARDS$530,177
R01 · FY2018 · HL · contact PI
Neutrophil-dependent mediators of sepsis$295,275
R01 · FY2018 · GM
MESO QuikPlex SQ 120 for the multiplex quantification of proteins in human biospecimens$50,025
S10 · FY2018 · OD · contact PI
Reconsidering the IL-1 axis in sepsis-associated ARDS$535,749
R01 · FY2017 · HL · contact PI
Targeting Angiopoietin-2 in ARDS$535,193
R01 · FY2017 · HL · contact PI
Interleukin-1 Receptor Antagonist in ARDS$614,248
R56 · FY2015 · HL · contact PI
Genetic Variation in the ANGPT-TIE Pathway and Risk for Acute Lung Injury$137,052
K23 · FY2014 · HL · contact PI
Genetic Variation in the ANGPT-TIE Pathway and Risk for Acute Lung Injury$137,052
K23 · FY2013 · HL · contact PI
Genetic Variation in the ANGPT-TIE Pathway and Risk for Acute Lung Injury$137,052
K23 · FY2012 · HL · contact PI
Genetic Variation in the ANGPT-TIE Pathway and Risk for Acute Lung Injury$137,052
K23 · FY2011 · HL · contact PI
Genetic Variation in the ANGPT-TIE Pathway and Risk for Acute Lung Injury$137,052
K23 · FY2010 · HL · contact PI
Role of Growth Arrest and DNA Damage 45-alpha in Acute Lung Injury Pathogenesis$56,702
F32 · FY2007 · HL · contact PI